Investor Newsletter

Issue 01 2022

MicroPort®

TARGET PREMIER Clinical Study for MicroPort® Next Generation Rapamycin Target Eluting Stent Completes First Patient Enrollment

Recently, the TARGET PREMIER project, a pre-market clinical study of the next-generation rapamycin target eluting coronary stent, initiated by Shanghai MicroPort Medical (Group) Ltd. (MicroPort®), has enrolled its first patient. The patient was recruited by the trial's lead investigator, Prof. Zhixiong Zhong of Meizhou People's Hospital in China.

"MicroPort® Firehawk® stent has shown good results in clinical use. The trial stent in the TARGET PREMIER study also uses the same technology of drug delivery in the tiny grooves on the non-luminal surface of the stent beam to achieve targeted release, with optimized stent structure," noted Prof. Zhixiong Zhong. "We are confident that the clinical study will be successfully completed. As the project leader, our research team is committed to completing the study with high efficiency and quality to provide new options for cardiovascular physicians in the process of coronary intervention."

According to Mr. Ming Zheng, Senior Vice President of Clinical Medicine at MicroPort®, since the launch of the first-generation product in 2014, Firehawk® stents have become globally leading solutions for their representation of the new standard of the next-generation cardiac stents. Maintaining a high level of investment in research and development and clinical trials, MicroPort® keeps conducting large-scale clinical studies for coronary stents around the world to enrich its cardiovascular interventional product line and bring benefits to more patients with coronary heart disease.

MicroPort

MicroPort® Orthopedics China Develops "Personalized" Artificial Wrist Prosthesis

Suzhou Minimally Invasive Orthopedics (Group) Co., Ltd. (MicroPort® Orthopedics China) has developed a "personalized and precise" wrist joint prosthesis, which was recently used during a wrist joint replacement surgery at the Institute of Traumatology and Orthopaedics of 920 Hospital. Following the surgery, led by Professor Yongqing Xu, the patient was able to rotate his wrist as normal for the first time in 18 years. As a wrist prosthesis perfectly matching the patient's condition, this product from MicroPort® Orthopedics China has already benefitted dozens of patients living with wrist deformities.



According to Mr. Zixin Weng, President of MicroPort® Orthopedics China, commented, "We are committed to becoming a trusted partner for medical professionals, helping patients regain normal joint mobility through in-depth collaboration with physicians. The development and clinical application of our new endeavor this time once again demonstrates MicroPort® Orthopedics' strength in R&D to deal with various complex and difficult cases, as well as our technology reserve to provide personalized and precise products. Based on clinical needs, MicroPort® Orthopedics will continue to introduce new treatment solutions and innovative products, and provide more comprehensive orthopedic medical total solutions for patients around the world."

MicroPort

MicroPort® Orthopedics Receives NMPA Marketing Approval for its Procotyl®-L Acetabular Cup System and Profemur® Preserve Hip Stem

Suzhou Minimally Invasive Orthopedics (Group) Co., Ltd. (MicroPort® Orthopedics) recently announced that it has received registration certificates from the National Medical Products Administration (NMPA) in China for two products, the Procotyl®-L acetabular cup system (Procotyl®-L) and the Profemur® Preserve hip stem. These two products have strong track record of clinical success. This recent milestone will further improve the hip replacement portfolio of MicroPort® Orthopedics in China.

Mr. Zixin Weng, President of MicroPort® Orthopedics China, commented, "The vision of MicroPort® Orthopedics is to create a complete product portfolio and provide total medical solutions for patients. As a leading global developer and manufacturer of high-end medical devices in this rapidly aging world, we will further improve the joint product line of MicroPort® Orthopedics by adhering to the MicroPort® philosophy of 'The Patient Always Comes First,' providing more accessible medical solutions for the targeted treatment of patients with bone and joint diseases in China."

MicroPort® CRM Receives Approval in Japan for Alizea™ Bluetooth® Pacemaker

MicroPort® CRM, a pioneering company in the field of Cardiac Rhythm Management, headquartered in France, recently received PMDA Japanese regulation agency approval for its latest range of implantable pacemakers, Alizea™. The devices are equipped with Bluetooth® technology for streamlined remote monitoring when paired with MicroPort® CRM's SmartView Connect™ home monitor, already approved in Japan.

Noboru Shimizu, VP of MicroPort® CRM Sales Japan, commented, "Around 64,000 patients are implanted with a pacemaker each year in Japan, and coupled with the difficulties that have arisen from the current health crisis, there is a growing need to monitor patients remotely, without them having to travel. Thanks to Alizea™ pacemakers and its SmartView Connect™ monitor, we are positioning ourselves in the Japanese market with the very best in cardiac pacing. I am convinced that this will allow us to strengthen our presence in Japan."

Benoît Clinchamps, President of MicroPort® CRM, noted, "We successfully launched Alizea™ in Europe in June 2021, and Japan is the second region to benefit from its advanced technological functions. As part of our commitment to improve the lives of as many patients as possible, and to support healthcare professionals in their mission, we will continue to deploy Alizea™ and SmartView Connect™ around the world."

Subject Enrollment Completed for Pre-market Clinical Study of MSC's BonaFire® Lead

MicroPort Soaring CRM (Shanghai) Co., Ltd. (MSC) recently announced the enrollment of the final two patients for the pre-market clinical study of the BonaFire® MRI compatible lead (BonaFire® lead) at the Zhongshan Hospital of Fudan University and the Tongji Hospital affiliated to Tongji Medical School of Huazhong University of Science and Technology, respectively, marking the completion of subject enrollment for the study.

Mr. Xiaoming Zhu, General Manager of MSC, said, "With full adherence to international standards, the BonaFire® lead is developed using state-of-the-art mainstream technologies, such as the controlled steroid-eluting mechanism, titanium nitride coating, and silicone-rubber-insulated layer. We also strive for excellence in material selection, structural design, and manufacturing processes. The completion of subject enrollment marks a major step forward in bringing BonaFire® to market. We hope that BonaFire® will fill a market gap in China as soon as possible to help more patients with cardiac arrhythmia. At the same time, MSC will continue to address the clinical needs of Chinese patients and physicians by promoting localized technological development and manufacturing in the field of heart rhythm management for more inclusive and accessible total medical solutions for cardiac rhythm diseases."

Endovastec™ Talos™ Thoracic Stent Graft System Receives NMPA Approval for Marketing



Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) recently received a registration certificate from China's National Medical Products Administration (NMPA) for its independently developed Talos™ Thoracic Stent Graft System (Talos™).

Mr. Qing Zhu, President of Endovastec™, said, "We are excited to welcome another independently developed product of Endovastec™ and obtaining marketing approval through 'Green Path'. In 2021, new products such as the Fontus™ branched stent graft system in surgical operation and the Talos™ thoracic stent graft system have entered the market, further enriching our existing aortic portfolio. In the future, we will continue to enhance our core competitiveness by focusing on unmet clinical demands, accelerating technological innovation, and improving product diversification."

MicroPort

MicroPort NeuroTech™ Receives NMPA Marketing Approval for its Diveer® Intracranial Balloon Catheter

MicroPort NeuroTech Limited (MicroPort NeuroTech™) has received marketing approval from China's National Medical Products Administration (NMPA) for its independently-developed Diveer® Intracranial Balloon Catheter (Diveer®).

The market approval of the Diveer® Intracranial Balloon Catheter further enhances MicroPort NeuroTech™'s product portfolio for the treatment of ICAS and provides more options for clinical practices. MicroPort NueroTech™ will continue to promote product innovation and improve its universal, affordable and comprehensive medical solutions for hemorrhagic stroke, intracranial atherosclerotic stenosis, and acute ischemic stroke.



MicroPort

First Patient Enrolled in MicroPort NueroTech™ PROMISE Study for Rebridge® Intracranial Visualized Stent

MicroPort NeuroTech Limited (MicroPort NeuroTech™) recently announced that it has enrolled the first patient in the PROMISE Study, a pre-market clinical study for the Rebridge® Intracranial Visualized Stent (Rebridge®), bringing the product into the clinical enrollment phase.

Mr. Zhiyong Xie, President of MicroPort NeuroTech™, said, "We are pleased to see that the performance of Rebridge® is being recognized by clinicians. This brings MicroPort NeuroTech™ one step closer to its goal of providing a total medical solution for stroke patients. We believe that through the efforts of all investigators, the PROMISE study will provide scientific evidence for Rebridge® and promote the product launch for the benefit of more patients."

MicroPort® Toumai® Surgical Robot Receives NMPA Approval, Becoming the First Commercialized Four-Arm Laparoscopic Surgical Robot Developed in China

Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort® MedBot®) recently announced that its Toumai® Laparoscopic Surgical Robot (MicroPort® Toumai®) was approved for marketing by the National Medical Products Administration (NMPA), making it the first four-arm laparoscopic robot approved for marketing developed by a Chinese company. The launch of MicroPort® Toumai® marks a major breakthrough in the field of Chinese laparoscopic surgical robots, rapidly improving the clinical performance of robotic surgery in China.

Dr. Chao He, President of MicroPort® MedBot®, commented, "MicroPort® Toumai® is the first Chinese developed four-arm laparoscopic robotic system approved by NMPA, marking a major breakthrough in the commercialization of China's surgical robots and the clinical application of robotic-assisted surgeries. As MicroPort® Toumai® becomes commercially available, it will bring benefits to patients who are in desperate need for inclusive robotic solutions. We will maintain innovation, strengthen the integration of industries, deepen the medical-industrial cooperation, and accelerate the product iteration, in order to provide patients and physicians with inclusive total surgical solutions based on intelligent robotics."

Toumai® Laparoscopic Surgical Robot by MicroPort® MedBot® Completes Enrollment for Multidisciplinary, Multicenter-Registered Clinical Trial

On January 22, 2022, the Toumai® laparoscopic surgical robot (Toumai®), developed by Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort® MedBot®), successfully performed two hepatotomy surgeries in Gansu Provincial People's Hospital. The surgeries, led by Dr. Yuntao Mafrom the Department of General Surgery, marks the completion of all surgical cases in the multidisciplinary, multicenter-registered clinical trials.

According to Mr. Yu Liu, Chief Commercial Officer of MicroPort® MedBot®, "Through the joint efforts of experts and teams from different clinical centers, we have successfully completed the enrollment of patients in multidisciplinary, multicenter-registered clinical trials.. The Toumai® clinical trials cover a wide range of difficult and complex surgeries in thoracic, abdominal, and pelvic cavities, demonstrating the leading position of Toumai® in China's laparoscopic robot development for clinical applications. These registered clinical trials have also demonstrated the ability of MicroPort® MedBot®'s R&D, clinical, and customer service teams to collaborate with each other on intensive surgical operations and quick response to clinical feedbacks. This has laid a solid foundation for the promotion of Toumai® after its launch to the market."

MicroPort

Single-Use Flexible Ureteropelvic Electronic Endoscopic Catheter developed by MicroPort® Urocare Approved for Marketing

MicroPort Urocare Medical Technology (Jiaxing) Co., Ltd. (MicroPort® Urocare) recently obtained medical device registration certification for its single-use flexible ureteropelvic electronic endoscopic catheter from the Zhejiang Provincial Drug Administration. This is the first registration certificate that MicroPort® Urocare has obtained since its establishment in the endoscopic product category in 2017.

According to Mr. Yiyun Que, Senior Vice President of Smart Manufacturing and Global Supply Chain of MicroPort® and Chairman of MicroPort® Urocare, "So far, MicroPort® Urocare has obtained 15 registration certificates, which completes our product portfolio in the field of urological stone consumables. The launch of the single-use flexible ureteropelvic electronic endoscopic catheter is a strategic breakthrough for MicroPort® Urocare to successfully compete in the field of endoscopic solutions. We will continue to focus on clinical needs, accelerate the pace of technological innovation, and deepen our efforts in the fields of non-vascular intervention and endoscopic treatment."

MicroPort



MicroPort® HorizonMedical™ Receives Marketing Approval for Two Oocyte Retrieval Needles

Shanghai Horizon Medical Technology Co., Ltd. (HorizonMedical™), recently received registration approval from the Zhejiang Medical Products Administration for its LOTUS™-SGN Single-use Sterile Single Lumen Ovum Aspiration Needle (LOTUS™-SGN) and LOTUS™ Double Lumen Ovum Aspiration Needle (LOTUS™ Double).

As an innovative company specialized in providing medical technology solutions for assisted reproduction, HorizonMedical™ offers a range of products including oocyte retrieval needles, embryo transfer catheters, and insemination catheters. The approval of LOTUS™ II-SGN and LOTUS™ Double further enriches the product portfolio of HorizonMedical™. In the future, HorizonMedical™ will continue to invest in research and development as well as product innovation to provide inclusive and accessible total medical solutions in the field of assisted reproduction.

REVEDA Establishes Joint Venture with Hybio Pharmaceutical on Drug-Device Combination Products

Suzhou Reveda Medical Co., Ltd. (REVEDA), recently announced that it has entered into an agreement with Hybio Pharmaceutical Co., Ltd. (Hybio Pharmaceutical) to establish a joint venture for drug-device combination products and collaborate in the field of polypeptide micro-needles for transdermal delivery. The joint venture will be 60% owned by REVEDA Medical and 40% by Hybio Pharmaceutical.

Mr. Shaogui Zeng, Chairman of Hybio Pharmaceutical, stated, "Collaboration with REVEDA of MicroPort® is yet another important step in Hybio Pharmaceutical's strategy of 'combination of innovative and generic products'. Over the past two decades, Hybio Pharmaceutical has been committed to the research, development, manufacturing, and marketing of peptides. We will continue to work with our partners to develop and promote peptides in new dosage forms, for new indications, and in new fields of application. The partnership with REVEDA means synergy and innovation. It allows us to unleash the strengths of both companies and join forces to explore better drug delivery solutions for the benefit of patients."

Ms. He Li, Chairman of the Board of Directors of REVEDA, commented, "It is our pleasure to enter into this strategic partnership with Hybio Pharmaceutical. We firmly believe that by combining the leading strengths and resources in our respective fields of research, we will be able to continue to innovate and advance in the field of peptide microneedles for transdermal drug delivery. By continuing to translate our advanced technologies into microneedle medical applications, we aim to provide customized and highly efficient solutions for patients in China and around the world."

MicroPort

Investor Newsletter

Issue 01 2022

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & VP of Securities Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com